NO327404B1 - Komplekser av LHRH antagonisten cetrorelix med polyaminosyrer, fremgangsmate for fremstilling av immobiliserte og aktivitetsstabiliserte peptidhormonpreparater fra komplekser av LHRH antagonisten, samt medikamenter inneholdende forbindelsene. - Google Patents
Komplekser av LHRH antagonisten cetrorelix med polyaminosyrer, fremgangsmate for fremstilling av immobiliserte og aktivitetsstabiliserte peptidhormonpreparater fra komplekser av LHRH antagonisten, samt medikamenter inneholdende forbindelsene. Download PDFInfo
- Publication number
- NO327404B1 NO327404B1 NO19994665A NO994665A NO327404B1 NO 327404 B1 NO327404 B1 NO 327404B1 NO 19994665 A NO19994665 A NO 19994665A NO 994665 A NO994665 A NO 994665A NO 327404 B1 NO327404 B1 NO 327404B1
- Authority
- NO
- Norway
- Prior art keywords
- complexes
- acid
- lhrh antagonist
- cetrorelix
- polyamino
- Prior art date
Links
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 title claims description 24
- 229960003230 cetrorelix Drugs 0.000 title claims description 21
- 108700008462 cetrorelix Proteins 0.000 title claims description 21
- 229920001308 poly(aminoacid) Polymers 0.000 title claims description 15
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims description 12
- 239000002474 gonadorelin antagonist Substances 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 11
- 239000000813 peptide hormone Substances 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000003814 drug Substances 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 title claims description 7
- 229940079593 drug Drugs 0.000 title claims description 5
- 229940088597 hormone Drugs 0.000 claims description 12
- 239000005556 hormone Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 9
- 229920002643 polyglutamic acid Polymers 0.000 claims description 9
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 7
- 108010064470 polyaspartate Proteins 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 201000009273 Endometriosis Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 201000001514 prostate carcinoma Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 208000021267 infertility disease Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 238000003744 In vitro fertilisation Methods 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000002253 acid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19712718A DE19712718C2 (de) | 1997-03-26 | 1997-03-26 | Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung |
PCT/EP1998/001398 WO1998042381A1 (de) | 1997-03-26 | 1998-03-11 | Immobilisierte und aktivitätsstabilisierte komplexe von lhrh-antagonisten und verfahren zu deren herstellung |
Publications (3)
Publication Number | Publication Date |
---|---|
NO994665L NO994665L (no) | 1999-09-24 |
NO994665D0 NO994665D0 (no) | 1999-09-24 |
NO327404B1 true NO327404B1 (no) | 2009-06-22 |
Family
ID=7824698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19994665A NO327404B1 (no) | 1997-03-26 | 1999-09-24 | Komplekser av LHRH antagonisten cetrorelix med polyaminosyrer, fremgangsmate for fremstilling av immobiliserte og aktivitetsstabiliserte peptidhormonpreparater fra komplekser av LHRH antagonisten, samt medikamenter inneholdende forbindelsene. |
Country Status (27)
Country | Link |
---|---|
US (2) | US6022860A (zh) |
EP (1) | EP0981377B1 (zh) |
JP (1) | JP4180120B2 (zh) |
CN (1) | CN1150943C (zh) |
AR (1) | AR012186A1 (zh) |
AT (1) | ATE249245T1 (zh) |
AU (1) | AU747808B2 (zh) |
BR (1) | BR9807887B1 (zh) |
CA (1) | CA2285054C (zh) |
CZ (1) | CZ300755B6 (zh) |
DE (2) | DE19712718C2 (zh) |
DK (1) | DK0981377T3 (zh) |
ES (1) | ES2206912T3 (zh) |
HK (1) | HK1025255A1 (zh) |
HU (1) | HUP0002059A3 (zh) |
IL (1) | IL131181A (zh) |
NO (1) | NO327404B1 (zh) |
NZ (1) | NZ337343A (zh) |
PL (1) | PL190090B1 (zh) |
PT (1) | PT981377E (zh) |
RU (1) | RU2207151C2 (zh) |
SK (1) | SK284461B6 (zh) |
TR (1) | TR199902168T2 (zh) |
TW (1) | TW520288B (zh) |
UA (1) | UA69381C2 (zh) |
WO (1) | WO1998042381A1 (zh) |
ZA (1) | ZA982225B (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
EP0788799A3 (en) | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
AU752415B2 (en) * | 1998-04-23 | 2002-09-19 | Zentaris Ivf Gmbh | Method for the treatment of fertility disorders |
CO5160256A1 (es) * | 1999-02-08 | 2002-05-30 | Zentaris Ag | Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion |
DE10024451A1 (de) * | 2000-05-18 | 2001-11-29 | Asta Medica Ag | Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung |
US7037889B2 (en) | 2000-09-13 | 2006-05-02 | Praecis Pharmaceuticals Inc. | Pharmaceutical compositions for sustained drug delivery |
US20020169125A1 (en) * | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
WO2003005889A2 (en) * | 2001-07-10 | 2003-01-23 | Ams Research Corporation | Surgical kit for treating prostate tissue |
US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
US8093207B2 (en) * | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
EP2099375B1 (en) | 2007-01-02 | 2014-09-24 | AquaBeam LLC | Minimally invasive devices for the treatment of prostate diseases |
US9232959B2 (en) | 2007-01-02 | 2016-01-12 | Aquabeam, Llc | Multi fluid tissue resection methods and devices |
JP5506702B2 (ja) | 2008-03-06 | 2014-05-28 | アクアビーム エルエルシー | 流体流れ内を伝達される光学エネルギーによる組織切除および焼灼 |
US9848904B2 (en) | 2009-03-06 | 2017-12-26 | Procept Biorobotics Corporation | Tissue resection and treatment with shedding pulses |
WO2010110455A1 (ja) * | 2009-03-27 | 2010-09-30 | 国立大学法人 鹿児島大学 | 疎水化ポリアミノ酸からなるポリイオンコンプレックスとその用途 |
JP6080872B2 (ja) | 2012-02-29 | 2017-02-15 | プロセプト バイオロボティクス コーポレイション | 自動化された画像誘導組織切除および治療 |
CN105431096B (zh) | 2013-02-14 | 2018-07-31 | 普罗赛普特生物机器人公司 | 液体消融液体束眼外科手术的方法和装置 |
CN109965976B (zh) | 2013-09-06 | 2022-05-31 | 普罗赛普特生物机器人公司 | 利用致脱脉冲的用于消融组织的装置 |
BR112016031037B1 (pt) | 2014-06-30 | 2023-02-07 | Procept Biorobotics Corporation | Aparelho para ablação de tecido vascular |
BR112017004431B1 (pt) | 2014-09-05 | 2022-11-01 | Procept Biorobotics Corporation | Aparelho para tratar um paciente |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE257197C (zh) * | ||||
US4341767A (en) * | 1980-10-06 | 1982-07-27 | Syntex Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
DD257197A1 (de) * | 1987-01-28 | 1988-06-08 | Univ Dresden Tech | Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen |
US4801577A (en) * | 1987-02-05 | 1989-01-31 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists |
DD269785A1 (de) * | 1988-02-08 | 1989-07-12 | Univ Dresden Tech | Verfahren zur herstellung von aktivitaetsstabilisierten und in ihren pharmakologischen eigenschaften modifizierten peptidderivaten |
DD273980B5 (de) * | 1988-07-12 | 1994-04-14 | Berlin Chemie Ag | Verfahren zur Herstellung von Insulin-Pr{paraten zur rektalen Anwendung |
ES2081384T3 (es) * | 1990-04-25 | 1996-03-01 | Hoechst Ag | Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa. |
DD299265A5 (de) * | 1990-09-11 | 1992-04-09 | Technische Universitaet Dresden,De | Verfahren zur herstellung von immobilisierten und aktivitaetsstabilisierten praeparaten des gonadotropin-releasing-hormons oder dessen analoga mit polyaminosaeuren |
US5834520A (en) * | 1992-10-08 | 1998-11-10 | Asta-Medica Aktiengesellschaft | Container for injectable mesna solutions |
EP0670728A4 (en) * | 1992-11-12 | 1996-04-17 | Molecular Dynamics Inc | PIPTIDE-BASED LIPOPHILE-BASED CARRIERS FOR TARGETED MEDICINE ADMINISTRATION USING A RATIONAL MEDICINE-BINDING DESIGN. |
DE4305225A1 (de) * | 1993-02-19 | 1994-08-25 | Asta Medica Ag | Neues Herstellverfahren für Cetrorelix Lyophilisat |
US5449720A (en) * | 1993-05-24 | 1995-09-12 | Biotech Australia Pty Limited | Amplification of the VB12 uptake system using polymers |
US5502035A (en) * | 1993-08-06 | 1996-03-26 | Tap Holdings Inc. | N-terminus modified analogs of LHRH |
CA2178592C (en) * | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
-
1997
- 1997-03-26 DE DE19712718A patent/DE19712718C2/de not_active Expired - Fee Related
-
1998
- 1998-03-11 PL PL98335830A patent/PL190090B1/pl not_active IP Right Cessation
- 1998-03-11 PT PT98914877T patent/PT981377E/pt unknown
- 1998-03-11 CA CA002285054A patent/CA2285054C/en not_active Expired - Fee Related
- 1998-03-11 CN CNB988031515A patent/CN1150943C/zh not_active Expired - Fee Related
- 1998-03-11 WO PCT/EP1998/001398 patent/WO1998042381A1/de active IP Right Grant
- 1998-03-11 RU RU99123056/14A patent/RU2207151C2/ru active
- 1998-03-11 CZ CZ0337199A patent/CZ300755B6/cs not_active IP Right Cessation
- 1998-03-11 IL IL13118198A patent/IL131181A/en not_active IP Right Cessation
- 1998-03-11 HU HU0002059A patent/HUP0002059A3/hu unknown
- 1998-03-11 TR TR1999/02168T patent/TR199902168T2/xx unknown
- 1998-03-11 JP JP54481198A patent/JP4180120B2/ja not_active Expired - Fee Related
- 1998-03-11 NZ NZ337343A patent/NZ337343A/en unknown
- 1998-03-11 SK SK1316-99A patent/SK284461B6/sk not_active IP Right Cessation
- 1998-03-11 DE DE59809575T patent/DE59809575D1/de not_active Expired - Fee Related
- 1998-03-11 BR BRPI9807887-9A patent/BR9807887B1/pt not_active IP Right Cessation
- 1998-03-11 AT AT98914877T patent/ATE249245T1/de not_active IP Right Cessation
- 1998-03-11 ES ES98914877T patent/ES2206912T3/es not_active Expired - Lifetime
- 1998-03-11 AU AU69207/98A patent/AU747808B2/en not_active Ceased
- 1998-03-11 EP EP98914877A patent/EP0981377B1/de not_active Expired - Lifetime
- 1998-03-11 DK DK98914877T patent/DK0981377T3/da active
- 1998-03-17 ZA ZA9802225A patent/ZA982225B/xx unknown
- 1998-03-23 TW TW087104303A patent/TW520288B/zh not_active IP Right Cessation
- 1998-03-26 AR ARP980101397A patent/AR012186A1/es active IP Right Grant
- 1998-03-26 US US09/048,244 patent/US6022860A/en not_active Expired - Fee Related
- 1998-11-03 UA UA99105810A patent/UA69381C2/uk unknown
-
1999
- 1999-09-24 NO NO19994665A patent/NO327404B1/no not_active IP Right Cessation
- 1999-10-22 US US09/422,990 patent/US6054555A/en not_active Expired - Fee Related
-
2000
- 2000-07-24 HK HK00104545A patent/HK1025255A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO327404B1 (no) | Komplekser av LHRH antagonisten cetrorelix med polyaminosyrer, fremgangsmate for fremstilling av immobiliserte og aktivitetsstabiliserte peptidhormonpreparater fra komplekser av LHRH antagonisten, samt medikamenter inneholdende forbindelsene. | |
AU769658B2 (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
EP0678018B1 (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
CA2046830C (en) | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer | |
US5672659A (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
US5972891A (en) | Sustained-release preparation | |
RU2103005C1 (ru) | Фармацевтическая композиция продленного действия, используемая в ней полимерная композиция и способ ее получения | |
US5863985A (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
CZ293794A3 (en) | Salts of peptides with polyesters having a terminal carboxyl group | |
AU2003264305B2 (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
MXPA99007545A (en) | Immobilized activity stabilized lhrh antagonist complexes, method for the production thereof | |
EP1203591A1 (en) | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides | |
NZ527337A (en) | Ionic molecular conjugates of bio degradable polyesters and bioactive polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |